NASDAQ:TRAX First Tracks Biotherapeutics Q2 2026 Earnings Report $40.46 -2.05 (-4.82%) As of 09/4/2026 04:00 PM Eastern ProfileEarnings HistoryForecast First Tracks Biotherapeutics EPS ResultsActual EPS-$0.95Consensus EPS -$0.74Beat/MissMissed by -$0.21One Year Ago EPSN/AFirst Tracks Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AFirst Tracks Biotherapeutics Announcement DetailsQuarterQ2 2026Date8/12/2026TimeAfter Market ClosesConference Call DateWednesday, August 12, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) First Tracks Biotherapeutics Earnings HeadlinesFirst Tracks Biotherapeutics (NASDAQ:TRAX) Receives Average Rating of "Moderate Buy" from Analysts4 hours ago | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for First Tracks Biotherapeutics (NASDAQ:TRAX)4 hours ago | americanbankingnews.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 5 at 1:00 AM | The Oxford Club (Ad)First Tracks Biotherapeutics (NASDAQ:TRAX) Downgraded by Wall Street Zen to "Sell"September 5 at 1:36 AM | americanbankingnews.comFirst Tracks Biotherapeutics Inc (TRAX)August 30, 2026 | de.investing.comFirst Tracks Biotherapeutics Announces Participation in September Investor ConferencesAugust 26, 2026 | globenewswire.comSee More First Tracks Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like First Tracks Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on First Tracks Biotherapeutics and other key companies, straight to your email. Email Address About First Tracks BiotherapeuticsFirst Tracks Biotherapeutics (NASDAQ:TRAX) is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.View First Tracks Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake’s AI Momentum Is Forcing a Fresh Look at the StockAeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityFB Financial's Southern Expansion and Buybacks Drive Analyst OptimismRetail Earnings Just Exposed a Bigger Divide in the U.S. Consumer EconomyAccelerant’s Take-Private Deal Raises a Bigger Question for Insurance StocksDefense Stocks Are Pulling Back as Their Navy Tailwinds Get StrongerThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
